CB1 selective antagonists show clinical efficacy in the treatment of obesity, metabolic disorders, and drug abuse [39,40], whereas CB2 selective agents demonstrate efficacy in inflammatory pain models [41] and play neuroprotective roles in Huntington’s and Alzheimer’s diseases [42,43]. The gene discussed is CNR2; the disease is Other metabolic disease.